Design Therapeutics (DSGN) Other Operating Expenses (2025)
Design Therapeutics recorded quarterly Other Operating Expenses of $59.0 million in Q4 2025, up 1166.17% quarter-over-quarter from $4.7 million in Q3 2025.
Design Therapeutics' Other Operating Expenses history runs 1 years deep, the most recent figure standing at $59.0 million for Q4 2025.
- In Q4 2025, Other Operating Expenses changed N/A year-over-year to $59.0 million; the TTM figure through Mar 2026 stood at $63.7 million (changed N/A YoY), while the FY2025 annual figure was $59.0 million, changed N/A from the prior year.
- Other Operating Expenses came in at $59.0 million for Q4 2025 at Design Therapeutics, up from $4.7 million in the prior quarter.
- In the past five years, Other Operating Expenses ranged from a high of $59.0 million in Q4 2025 to a low of $4.7 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Design Therapeutics | 640.15 Mn | 417.32 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 59.03 Mn |
| Sep 30, 2025 | 4.66 Mn |